PRECISION BIOSCIENCES INC (DTIL) Stock Price & Overview
NASDAQ:DTIL • US74019P2074
Current stock price
The current stock price of DTIL is 7.53 USD. Today DTIL is down by -1.7%. In the past month the price increased by 10.53%. In the past year, price increased by 52.59%.
DTIL Key Statistics
- Market Cap
- 186.217M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.13
- Dividend Yield
- N/A
DTIL Stock Performance
DTIL Stock Chart
DTIL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DTIL. When comparing the yearly performance of all stocks, DTIL is one of the better performing stocks in the market, outperforming 92.8% of all stocks.
DTIL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DTIL. The financial health of DTIL is average, but there are quite some concerns on its profitability.
DTIL Earnings
On March 12, 2026 DTIL reported an EPS of 1.05 and a revenue of 34.20M. The company beat EPS expectations (292.41% surprise) and beat revenue expectations (269.49% surprise).
DTIL Forecast & Estimates
10 analysts have analysed DTIL and the average price target is 32.64 USD. This implies a price increase of 333.47% is expected in the next year compared to the current price of 7.53.
For the next year, analysts expect an EPS growth of 37.02% and a revenue growth 47.98% for DTIL
DTIL Groups
Sector & Classification
DTIL Financial Highlights
Over the last trailing twelve months DTIL reported a non-GAAP Earnings per Share(EPS) of -5.13. The EPS decreased by -3320% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.61% | ||
| ROE | -49.57% | ||
| Debt/Equity | 0.24 |
DTIL Ownership
DTIL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.09 | 368.645B | ||
| AMGN | AMGEN INC | 15.3 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.67 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.37 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.91 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.9 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 10.92 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.86 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.32 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DTIL
Company Profile
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 68 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.
Company Info
IPO: 2019-03-28
PRECISION BIOSCIENCES INC
302 E Pettigrew St Ste A100
Durham NORTH CAROLINA 27701 US
CEO: Matthew Kane
Employees: 68
Phone: 13026587581
PRECISION BIOSCIENCES INC / DTIL FAQ
Can you describe the business of PRECISION BIOSCIENCES INC?
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 68 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.
What is the stock price of PRECISION BIOSCIENCES INC today?
The current stock price of DTIL is 7.53 USD. The price decreased by -1.7% in the last trading session.
What is the dividend status of PRECISION BIOSCIENCES INC?
DTIL does not pay a dividend.
What is the ChartMill rating of PRECISION BIOSCIENCES INC stock?
DTIL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting DTIL stock to perform?
10 analysts have analysed DTIL and the average price target is 32.64 USD. This implies a price increase of 333.47% is expected in the next year compared to the current price of 7.53.
Can you provide the market cap for PRECISION BIOSCIENCES INC?
PRECISION BIOSCIENCES INC (DTIL) has a market capitalization of 186.22M USD. This makes DTIL a Micro Cap stock.